GlassScriptPhysician profile
Charles R Byrd
NPI 1225056328
$14,590.66
in general payments reported to CMS, 2019-2025
59 companies · $2,324 in 2025
The $2,324 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,764 · 2020: $2,137 · 2021: $2,505 · 2022: $1,875 · 2023: $2,064 · 2024: $1,922 · 2025: $2,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,307 · Education: $3.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,306.87 |
| Education | $3.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,025.49 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,181.43 | 2019-2025 | |
| Gilead Sciences, INC. | $1,128.36 | 2019-2025 | |
| Amgen INC. | $1,000.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $874.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $797.68 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $784.86 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $757.59 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $580.83 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Allergan, INC. | $545.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.86 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.70 | 2019-2025 | Xifaxan |
| Amneal Pharmaceuticals LLC | $312.34 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $289.21 | 2019-2023 | Ajovy |
| Janssen Pharmaceuticals, INC | $261.98 | 2020-2025 | Spravato |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.